latamoxef

Latamoxef (also known as moxalactam) is a synthetic oxacephem antibiotic, structurally related to the cephalosporins but with an oxygen atom replacing the sulfur in the core ring. It is classified as a third-generation cephalosporin and exhibits broad-spectrum activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria, particularly Enterobacteriaceae. Latamoxef acts by inhibiting bacterial cell wall biosynthesis through binding to penicillin-binding proteins (PBPs), thereby blocking peptidoglycan cross-linking essential for cell wall integrity. This leads to bacterial lysis via autolytic enzymes. It is resistant to hydrolysis by many beta-lactamases but has only moderate activity against Pseudomonas aeruginosa. Clinically, it was used for bone and joint infections, gastrointestinal infections, gynecological infections, meningitis, respiratory tract infections, septicemia, skin/soft tissue infections, and urinary tract infections. Notably, it can cause coagulopathy due to its methylthiotetrazole side chain interfering with vitamin K metabolism; it may also provoke disulfiram-like reactions with alcohol use[1][2][3][4][5].

Brand names

MoxamBaxalBetalactamFestamoxinLatoxacetMactamMoxacefMoxatresPriollatSectamShiomalinShiomarin

Other names

moxalactamlamoxactamlatamoxefumoxa-cephmLMOX